One or two probes for heat treatment of cervical precancer in women with HIV
Compares one or two heat probes for cervical precancer in women with HIV.
Plain-language title generated from the registry record
Registry title: Feasibility Study Comparing Use of One Or Two Probes for Thermal Ablation Among Screen Positive Women Living With HIV in C1001P-CS2 Kenya
Key facts
- Where
- Nairobi, KenyaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 25 to 49 who live with HIV and have a positive cervical screening test. It compares heat treatment of the cervix with one probe or two probes.
- Age
- 25 to 49 years
- Sex
- Women only
- Disease stage
- Positive hrHPV or VIA test within 3 months of enrolment; type 1 transformation zone (TZ1); able to have thermal ablation; cervix still in place.
- Earlier treatment
- Cannot have had treatment for cervical precancer before. Cannot be getting treatment for any cancer now.
- Biomarker or test result
- Positive hrHPV or VIA test within 3 months of enrolment.
Main reasons for not taking part
- Screened for cervical cancer outside the study in the last 6 months
- Pregnant now or less than 6 weeks after giving birth
- Earlier diagnosis of cervical cancer
- Total hysterectomy
- Any condition the site investigator thinks could affect the study or put the person at unacceptable risk
This trial only enrols participants living with HIV. The registry sentence this rests on: Living with HIV
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 49 years old?
Source: NCT07468695, who can take part
Where in Kenya
- Coptic Hope CenterNairobi, KenyaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fred Hutchinson Cancer Center
- Trial code
- NCT07468695
- Record updated
- 3 November 2026
- Original description
Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. Thermal ablation (TA) is recommended by the World Health Organization (WHO) to treat cervical precancerous lesions, although its efficacy can be suboptimal in WLWH. In Kenya, the estimated incidence rate of cervical cancer is 31-33 per 100,000 women per year among women without HIV and approximately 70-100 per 100,000 among WLWH.Read full original descriptionShow less
Expanded Use of Thermal Ablation (EXCEL Cohort) and Prophylactic Use of Two Probes (PRO Cohort) for Cervical Cancer Prevention in Women Living With HIV
Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. Thermal ablation (TA) is recommended by the World Health Organization (WHO) to treat cervical precancerous lesions, although its efficacy can be suboptimal in WLWH. In Kenya, the estimated incidence rate of cervical cancer is 31-33 per 100,000 women per year among women without HIV and approximately 70-100 per 100,000 among WLWH.
The proposed study will evaluate the feasibility, acceptability, and safety of a two-probe TA technique (endocervical and ectocervical probes) and whether this approach improves treatment outcomes among WLWH compared to one (ectocervical) probe. This innovation has the potential to significantly enhance cervical cancer prevention efforts in high-burden settings. It will also contribute towards achieving the 90-70-90 goals of the WHO strategy for accelerated elimination of cervical cancer as a public health problem by 2030.
Inclusion: 25-49 years old; Living with HIV; Intact cervix; Willing to return to facility at 6 months; Willing and able to provide informed consent; Positive hrHPV or VIA test within 3 months of enrollment; Type 1 transformation zone (TZ1); Thermal ablation eligible.
Exclusion: Prior diagnosis of cervical cancer; Currently receiving treatment for any cancer; Screened for cervical cancer outside of study in last 6 months; A history of treatment for cervical precancer; Individual has a condition that the Clinical Site PI believes will interfere with or affect the conduct, results, or completion of the clinical study; Individual has a condition that the Clinical Site PI considers creates an unacceptable risk to the individual if enrolled; Currently pregnant or less than 6 weeks postpartum; Total hysterectomy.